{ "case_number": "CAC-UDRP-109006", "time_of_filling": "2026-09-17 09:39:52", "domain_names": [ "tevapharma.bio" ], "case_administrator": " Iveta Špiclová (Czech Arbitration Court) (Case admin)", "complainant": [ "Teva Pharmaceutical Industries Ltd." ], "complainant_representative": "SILKA AB", "respondent": [ "Whois Agent (Netlify Inc)" ], "respondent_representative": null, "factual_background": "

The Complainant is an international pharmaceutical company focused on advancing healthcare through the development, manufacture, and supply of high-quality medicinal products and healthcare solutions. Established in Israel on February 13, 1944, through the consolidation of several pharmaceutical enterprises, including one founded in 1901, the Complainant has grown into one of the world's foremost producers of generic medicines. Its activities encompass the research, development, production, and commercialization of innovative therapies, generic drugs, and biosimilar products designed to meet the healthcare needs of patients worldwide. In 2025, the Complainant reported revenues of approximately USD 17.3 billion across 57 markets, operated 30 manufacturing facilities, and employed approximately 34,000 individuals globally. <\/span><\/p>\n

The disputed domain name <tevapharma.bio> was registered on August 22, 2026 and resolves to a website that falsely presents itself as being associated with the Complaint, and provides e-mail addresses purportedly belonging to executives of the Complainant for business communications.<\/p>", "other_legal_proceedings": "

The Panel is not aware of any other legal proceedings which are pending or decided and which relate to the disputed domain name.<\/p>", "no_response_filed": "

COMPLAINANT:<\/span><\/p>\n

The Complainant contends that the disputed domain name is confusingly similar to the Trademark.<\/span><\/p>\n

Furthermore, the Complainant contends that the Respondent has no rights or legitimate interests in the disputed domain name. In this regard, the Complainant states that the Respondent is not commonly known by the disputed domain name, that it is not affiliated with nor authorized by the Complainant in any way, that the Complainant does not carry out any activity for, nor has any business with the Respondent, and that neither license nor authorization has been granted to the Respondent to make any use of the Trademark or apply for registration of the disputed domain name by the Complainant.<\/span>

<\/p>\n

Finally, the Complainant contends that the disputed domain name was registered and is being used in bad faith. It contends that the Respondent must have been aware of the Complainant and its Trademark at the time of registration of the disputed domain name, as the Trademark is well-known. Further, the Respondent's use of the disputed domain name is evidence of bad faith, as it is a deliberate attempt to exploit the reputation attached to the Trademark and to create confusion among Internet users as to the source, sponsorship, affiliation, or endorsement of the website.<\/span><\/p>\n

RESPONDENT:<\/span><\/p>\n

No administratively compliant Response has been filed.<\/p>", "rights": "

The Complainant has, to the satisfaction of the Panel, shown the disputed domain name is identical or confusingly similar to a trademark or service mark in which the Complainant has rights (within the meaning of paragraph 4(a)(i) of the Policy).<\/p>", "no_rights_or_legitimate_interests": "

The Complainant has, to the satisfaction of the Panel, shown the Respondent to have no rights or legitimate interests in respect of the disputed domain name (within the meaning of paragraph 4(a)(ii) of the Policy).<\/p>", "bad_faith": "

The Complainant has, to the satisfaction of the Panel, shown the disputed domain name has been registered and is being used in bad faith (within the meaning of paragraph 4(a)(iii) of the Policy).<\/p>", "procedural_factors": "

The Panel is satisfied that all procedural requirements under UDRP were met and there is no other reason why it would be inappropriate to provide a decision.<\/p>", "decision": "Accepted", "panelists": [ "Stefanie Efstathiou LL.M. mult." ], "date_of_panel_decision": "2026-10-14 00:00:00", "informal_english_translation": "

The Complainant owns<\/span> several \"TEVA\" and \"TEVAPHARM\" trademarks, registered worldwide, such as:<\/span><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n
\n

Trademark<\/strong><\/p>\n<\/td>\n

\n

Jurisdiction<\/strong><\/p>\n<\/td>\n

\n

Registration Number<\/strong><\/p>\n<\/td>\n

\n

Registration Date<\/strong><\/p>\n<\/td>\n

\n

Class(es) Covered<\/strong><\/p>\n<\/td>\n<\/tr>\n

\n

TEVA<\/a><\/span><\/p>\n

[Device]<\/p>\n<\/td>\n

\n

International<\/p>\n<\/td>\n

\n

1319184<\/p>\n<\/td>\n

\n

15 June 2016<\/p>\n<\/td>\n

\n

5, 10, 42<\/p>\n<\/td>\n<\/tr>\n

\n

TEVA<\/a><\/span><\/p>\n

[Device]<\/p>\n<\/td>\n

\n

European Union<\/p>\n<\/td>\n

\n

000115394<\/p>\n<\/td>\n

\n

29 April 1998<\/p>\n<\/td>\n

\n

5<\/p>\n<\/td>\n<\/tr>\n

\n

TEVA<\/a><\/span><\/p>\n<\/td>\n

\n

United States<\/p>\n<\/td>\n

\n

1567918<\/p>\n<\/td>\n

\n

28 November 1989<\/p>\n<\/td>\n

\n

5<\/p>\n<\/td>\n<\/tr>\n

\n

TEVA<\/a><\/span><\/p>\n<\/td>\n

\n

European Union<\/p>\n<\/td>\n

\n

007258081<\/p>\n<\/td>\n

\n

3 January 2011<\/p>\n<\/td>\n

\n

1, 3, 5, 10, 42<\/p>\n<\/td>\n<\/tr>\n

\n

TEVA<\/a><\/span><\/p>\n<\/td>\n

\n

Israel<\/p>\n<\/td>\n

\n

41075<\/p>\n<\/td>\n

\n

5 July 1977<\/p>\n<\/td>\n

\n

5<\/p>\n<\/td>\n<\/tr>\n

\n

TEVAPHARM<\/a><\/span><\/p>\n<\/td>\n

\n

United Kingdom<\/p>\n<\/td>\n

\n

UK00003577956<\/p>\n<\/td>\n

\n

21 May 2021<\/p>\n<\/td>\n

\n

5, 44<\/p>\n<\/td>\n<\/tr>\n

\n

TEVAPHARM<\/a><\/span><\/p>\n<\/td>\n

\n

European Union<\/p>\n<\/td>\n

\n

018285645<\/p>\n<\/td>\n

\n

9 January 2021<\/p>\n<\/td>\n

\n

5, 44<\/p>\n<\/td>\n<\/tr>\n

\n

TEVAPHARM<\/a><\/span><\/p>\n<\/td>\n

\n

Denmark<\/p>\n<\/td>\n

\n

VR 2011 02130<\/p>\n<\/td>\n

\n

31 August 2011<\/p>\n<\/td>\n

\n

5, 10, 35<\/p>\n<\/td>\n<\/tr>\n

\n

TEVAPHARMA<\/p>\n

(Official database does not provide a direct link to the trademark registration)<\/p>\n<\/td>\n

\n

Chile<\/p>\n<\/td>\n

\n

1280482<\/p>\n<\/td>\n

\n

31 Jan 2017<\/p>\n

(Filing date)<\/p>\n<\/td>\n

\n

5, 44<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

(hereinafter cumulatively referred to as the \"Trademark\").<\/span><\/p>", "decision_domains": { "tevapharma.bio": "TRANSFERRED" }, "panelist": null, "panellists_text": null }